Literature DB >> 31312413

Synthesis and Biological Activity of Peptide α-Ketoamide Derivatives as Proteasome Inhibitors.

Salvatore Pacifico1, Valeria Ferretti1, Valentina Albanese1, Anna Fantinati1, Eleonora Gallerani1, Francesco Nicoli1, Riccardo Gavioli1, Francesco Zamberlan2, Delia Preti1, Mauro Marastoni1.   

Abstract

Proteasome activity affects cell cycle progression as well as the immune response, and it is largely recognized as an attractive pharmacological target for potential therapies against several diseases. Herein we present the synthesis of a series of pseudodi/tripeptides bearing at the C-terminal position different α-ketoamide moieties as pharmacophoric units for the interaction with the catalytic threonine residue that sustains the proteolytic action of the proteasome. Among these, we identified the 1-naphthyl derivative 13c as a potent and selective inhibitor of the β5 subunit of the 20S proteasome, exhibiting nanomolar potency in vitro (β5 IC50 = 7 nM, β1 IC50 = 60 μM, β2 IC50 > 100 μM). Furthermore, it significantly inhibited proliferation and induced apoptosis of the human colorectal carcinoma cell line HCT116.

Entities:  

Year:  2019        PMID: 31312413      PMCID: PMC6627721          DOI: 10.1021/acsmedchemlett.9b00233

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  31 in total

1.  TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093. Taxonomy, production, isolation, and biological activities.

Authors:  Y Koguchi; J Kohno; M Nishio; K Takahashi; T Okuda; T Ohnuki; S Komatsubara
Journal:  J Antibiot (Tokyo)       Date:  2000-02       Impact factor: 2.649

Review 2.  The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction.

Authors:  Michael H Glickman; Aaron Ciechanover
Journal:  Physiol Rev       Date:  2002-04       Impact factor: 37.312

Review 3.  The development of proteasome inhibitors as anticancer drugs.

Authors:  Julian Adams
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

Review 4.  Proteolysis: from the lysosome to ubiquitin and the proteasome.

Authors:  Aaron Ciechanover
Journal:  Nat Rev Mol Cell Biol       Date:  2005-01       Impact factor: 94.444

Review 5.  20S proteasome and its inhibitors: crystallographic knowledge for drug development.

Authors:  Ljudmila Borissenko; Michael Groll
Journal:  Chem Rev       Date:  2007-02-23       Impact factor: 60.622

6.  The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study.

Authors:  M Groll; W Heinemeyer; S Jäger; T Ullrich; M Bochtler; D H Wolf; R Huber
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

7.  An efficient synthesis of the taxane-derived anticancer agent ABT-271.

Authors:  J A DeMattei; M R Leanna; W Li; P J Nichols; M W Rasmussen; H E Morton
Journal:  J Org Chem       Date:  2001-05-18       Impact factor: 4.354

8.  Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines.

Authors:  Hannes A Braun; Sumaira Umbreen; Michael Groll; Ulrike Kuckelkorn; Izabela Mlynarczuk; Moritz E Wigand; Ilse Drung; Peter-Michael Kloetzel; Boris Schmidt
Journal:  J Biol Chem       Date:  2005-05-26       Impact factor: 5.157

9.  QSAR studies on peptide alpha-ketoamides and alpha-ketohydroxamate derivatives as calpain I inhibitors.

Authors:  Jesse S Dondapati; Sudhakar Godi; Ajay P Babu
Journal:  J Enzyme Inhib Med Chem       Date:  2008-12       Impact factor: 5.051

10.  Arecoline tripeptide inhibitors of proteasome.

Authors:  Mauro Marastoni; Anna Baldisserotto; Alessandro Canella; Riccardo Gavioli; Carmela De Risi; Gian Piero Pollini; Roberto Tomatis
Journal:  J Med Chem       Date:  2004-03-11       Impact factor: 7.446

View more
  3 in total

1.  An insight into the interaction between α-ketoamide- based inhibitor and coronavirus main protease: A detailed in silico study.

Authors:  Snehasis Banerjee
Journal:  Biophys Chem       Date:  2020-11-28       Impact factor: 2.352

2.  A new class of α-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities.

Authors:  Juan Wang; Boqiang Liang; Yiling Chen; Jasper Fuk-Woo Chan; Shuofeng Yuan; Hui Ye; Linlin Nie; Jiao Zhou; Yi Wu; Meixian Wu; Lina S Huang; Jing An; Arieh Warshel; Kwok-Yung Yuen; Aaron Ciechanover; Ziwei Huang; Yan Xu
Journal:  Eur J Med Chem       Date:  2021-02-10       Impact factor: 6.514

3.  Direct oxidation of N-ynylsulfonamides into N-sulfonyloxoacetamides with DMSO as a nucleophilic oxidant.

Authors:  Jun Dong; Duo Fu; Dongning Sheng; Jiayi Wang; Jiaxi Xu
Journal:  RSC Adv       Date:  2021-12-20       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.